Two single-nucleotide polymorphisms with linkage disequilibrium in the human programmed cell death 5 gene 5′ regulatory region affect promoter activity and the susceptibility of chronic myelogenous leukemia in Chinese population

Clinical Cancer Research

Volumn 11, Issue 24, 2005, Pages 8592-8599

  Ma, Xi ^a   Ruan, Guorui ^c   Wang, Ying ^b   Li, Qiyan ^b   Zhu, Ping ^d   Qin, Ya Zhen ^c   Li, Jin Lan ^c   Liu, Yan Rong ^c   Ma, Dalong ^a   Zhao, Hongshan ^a  

^a PEKING UNIVERSITY   (China)

^b PEKING UNIVERSITY SCHOOL AND HOSPITAL OF STOMATOLOGY   (China)

^c PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^d PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

LUCIFERASE;

5' UNTRANSLATED REGION; ALLELE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER SUSCEPTIBILITY; CHINESE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; GENE; GENE EXPRESSION; GENE LINKAGE DISEQUILIBRIUM; GENE LOCATION; GENETIC ANALYSIS; GENETIC IDENTIFICATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MONONUCLEAR CELL; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROGRAMMED CELL DEATH 5 GENE; PROMOTER REGION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REPORTER GENE; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTION INITIATION SITE; TRANSCRIPTION REGULATION; WESTERN BLOTTING;

5' FLANKING REGION; APOPTOSIS REGULATORY PROTEINS; ASIAN CONTINENTAL ANCESTRY GROUP; BASE SEQUENCE; CASE-CONTROL STUDIES; CELL LINE, TUMOR; CHINA; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LEUKEMIA, MYELOID, CHRONIC; LEUKOCYTES, MONONUCLEAR; LINKAGE DISEQUILIBRIUM; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS (GENETICS); TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 29344449684     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0039     Document Type: Article

References (34)

1. Kelly LM, Gilliland DG. Genetics of myeloid leukemias. Annu Rev Genomics Hum Genet 2002;3:179-98.
2. Puil L, Liu J, Gish G, et al. Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J 1994;13:764-73.
3. Bedi A, Zehnbauer BA, Barber JP, Sharkis SJ, Jones RJ. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood 1994;83:2038-44.
4. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000;96:3343-56.
5. Jiang X, Lopez A, Holyoake T, Eaves A, Eaves C. Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia. Proc Natl Acad Sci U S A 1999;96:12804-9.
6. Liu HT, Wang YG, Zhang YM, et al. TFAR19, a novel apoptosis-related gene cloned from human leukemia cell line TF-1, could enhance apoptosis of some tumor cells induced by growth factor withdrawal. Biochem Biophys Res Commun 1999;254:203-10.
7. Song QS, Han WL, Liu HT, Ma DL. The cDNA cloning and sequencing of a novel mouse apoptosis related gene TFAR19. J Beijing Med Univ 1999;31:309-11.
8. Zhang YM, Xu XZ, Liu HT, Song QS, Ma DL. The apoptosis-accelerating effect of human recombinant TFAR19 protein on leukemia HL-60 cells. J Chin Immunol 2000;16:8-11.
9. Ruan GR, Chen SS, Chang Y, et al. Abnormal expression of a novel apoptosis promoting molecule TFAR19(PDCD5) in the bone marrow cells from adult chronic myeloid leukemia. Beijing Da Xue Xue Bao 2002;34:676-9.
10. Lech-Maranda E, Baseggio L, Bienvenu J, et al. Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma. Blood 2004;103:3529-34.
11. Gonzalez P, Diez-Juan A, Goto E, et al. A single-nucleotide polymorphism in the human p27kip1 gene (-838C>A) affects basal promoter activity and the risk of myocardial infarction. BMC Biol 2004;2:5.
12. Skoog T, van't Hooft FM, Kallin B, et al. A common functional polymorphism (C→A substitution at position -863) in the promoter region of the tumour necrosis factor-α (TNF-α) gene associated with reduced circulating levels of TNF-α. Hum Mol Genet 1999;8:1443-9.
13. Zhang J, Jin X, Fang S, et al. The functional SNP in the matrix metalloproteinase-3 promoter modifies susceptibility and lymphatic metastases in esophageal squamous cell carcinoma but not in gastric cardiac adenocarcinoma. Carcinogenesis 2004;25:2519-24.
14. Third MIC Cooperative Study Group. Recommendations for a morphologic, immunologic and cytogenetic (MIC) working classification of the primary and therapy related myelodysplastic disorders. Cancer Genet Cytogenet 1988;32:1-10.
15. Xu MX, Cheng N, Gui LM, et al. The 5′-upstream region of human programmed cell death 5 gene contains a highly active TATA-less promoter that is up-regulated byetoposide. Gene 2004;329:39-49.
16. Morrison VA. Chronic leukemias. CA Cancer J Clin 1994;44:353-77.
17. Brincker H. Population-based age-and sex-specific incidence rates in the 4 main types of leukemia. Scand J Haematol 1982;29:241-9.
18. Call TG, Phyliky RL, Noel P, et al. Incidence of leukemia in Olmsted County, Minnesota, 1935 through 1989, with emphasis on changes in initial stage at diagnosis. Mayo Clin Proc 1994;69:315-8.
19. Fialkow PJ. Cell lineages in hematopoietic neoplasia studied with glucose-6-phosphate dehydrogenase cell markers. J Cell Physiol Suppl 1982;1:37-43.
20. McGahon A, Bissonnette R, Schmitt M, Cotter KM, Green DR, Cotter TG. BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 1994;83:1179-87.
21. Dubrez L, Eymin B, Sordet O, Droin N, Turhan AG, Solary E. BCR-ABL delays apoptosis upstream of procaspase-3 activation. Blood 1998;91:2415-22.
22. Tournamille C, Colin Y, Cartron JP, LeVanKim C. Disruption of a GATA motif in the Duffy gene promoter abolishes erythroid gene expression in Duffy-negative individuals. Nat Genet 1995;10:224-8.
23. Knight JC, Udalova I, Hill AV, et al. A polymorphism that affects OCT-1 binding to the TNF promoter region is associated with severe malaria. Nat Genet 1999;22:145-50.
24. Udalova IA, Richardson A, Denys A, et al. Functional consequences of a polymorphism affecting NF-κB p50-p50 binding to the TNF promoter region. Mol Cell Biol 2000;20:9113-9.
25. Farzaneh-Far A, Davies JD, Braam LA, et al. A polymorphism of the human matrix γ-carboxyglutamic acid protein promoter alters binding of an activating protein-1 complex and is associated with altered transcription and serum levels. J Biol Chem 2001;276:32466-73.
26. Jean D, Gershenwald JE, Huang S, et al. Loss of AP-2 results in up-regulation of MCAM/MUC18 and an increase in tumor growth and metastasis of human melanoma cells. J Biol Chem 1998;273:16501-8.
27. Anttila MA, Kellokoski JK, Moisio KI, et al. Expression of transcription factor AP-2α predicts survival in epithelial ovarian cancer. Br J Cancer 2000;82:1974-83.
28. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002;108:153-64.
29. Bergamaschi D, Gasco M, Miller L, et al. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 2003;3:387-402.
30. Sullivan A, Syed N, Gasco M, et al. Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene 2004;23:3328-37.
31. Wang Y, Li X, Wang L, et al. An alternative form of paraptosis-like cell death, triggered by TAJ/TROY and enhanced by PDCD5 overexpression. J Cell Sci 2004; 117:1525-32.
32. Chen Y, Douglass T, Jeffes EWB, et al. Living T9 glioma cells expressing membrane macrophage colony-stimulating factor produce immediate tumor destruction by polymorphonuclear leukocytes and macrophages via a "paraptosis"-induced pathway that promotes systemic immunity against intracranial T9 gliomas. Blood 2002;100:1373-80.
33. Dal Canto MC, Gurney ME. Development of central nervous system pathology in a murine transgenic model of human amyotrophic lateral sclerosis. Am J Pathol 1994;145:1271-9.
34. He YL, Qi HY, Wen WJ, Wang H, Zhu TJ. Study on the expression of apoptosis-related molecule PDCD5 in the skin lesions of psoriasis. Chin J Dermatol 2004; 37:215-7.